SCHEMBL21775704

SCHEMBL21775704

COC(=O)c1cc(N(C)C)ccc1O

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 3/20 0.62
▸ CA1 P00915 3/20 0.62
▸ CA2 P00918 3/20 0.62
▸ CA7 P43166 3/20 0.62
▸ CA9 Q16790 3/20 0.62
▸ CA14 Q9ULX7 3/20 0.62
▸ TSHR P16473 3/20 0.52
▸ LMNA P02545 1/20 0.52
▸ PTGS2 P35354 1/20 0.51
▸ PDK2 Q15119 1/20 0.49
▸ PDK4 Q16654 1/20 0.49
▸ GAA P10253 2/20 0.46
▸ XDH P47989 1/20 0.46
▸ EGFR P00533 3/20 0.46
▸ NOX4 Q9NPH5 1/20 0.46
▸ PTPN11 Q06124 1/20 0.43
▸ NPC1 O15118 2/20 0.43
▸ SMN1; SMN2 Q16637 2/20 0.43
▸ KDM4E B2RXH2 1/20 0.43
▸ ALDH1A1 P00352 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3165135 0.86 CA12 (0.62) CA12CA1CA2CA7CA9
SCHEMBL8762164 0.85 CA12 (0.47) CA12CA1CA2CA7CA9
SCHEMBL30966775 0.84 KDM4E (0.47) CA12CA1CA2CA7CA9
SCHEMBL18015088 0.84 KDM4E (0.47) CA12CA1CA2CA7CA9
SCHEMBL27968758 0.81 CA12 (0.53) CA12CA1CA2CA7CA9
SCHEMBL25247275 0.81 ALDH1A1 (0.43) CA12CA1CA2CA7CA9
SCHEMBL1110957 0.81 ALDH1A1 (0.42) CA12CA1CA2CA7CA9
SCHEMBL1110933 0.81 ALDH1A1 (0.51) TSHRLMNAGAANPC1SMN1; SMN2
SCHEMBL19874811 0.81 SLC16A3 (0.44) CA12CA1CA2CA7CA9
SCHEMBL1129609 0.81 ALDH1A1 (0.58) TSHRLMNAGAANPC1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11692004-B2 Substituted pyrazole compound, preparation method therefor, pharmaceutical composition and medical use thereof JIANGSU VANGUARD PHARMACEUTICAL CO., LTD. (CN) 2023-07-04 — — US disclosed
US-11692004-B2 Substituted pyrazole compound, preparation method therefor, pharmaceutical composition and medical use thereof JIANGSU VANGUARD PHARMACEUTICAL CO., LTD. (CN) 2023-07-04 — — US disclosed
WO-2020038279-A1 SUBSTITUTED PYRAZOLE COMPOUND, AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION, AND USE THEREOF 天津谷堆生物医药科技有限公司 2020-02-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11692004-B2 Substituted pyrazole compound, preparation method therefor, pharmaceutical composition and medical use thereof FARS2, GOT2, HADHB CA12 4853/4885CA1 4417/4885CA2 4773/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback